Because of their low cost actos mechanism of action, DPP-4 inhibitors can be used as add-on therapy to other classes of drugs for treatment of type 2 diabetes. The addition of either sitagliptin or ...
Takeda announced positive late-stage results for its new type 2 diabetes drug, fasiglifam (TAK-875), the first GPR40 agonist to reach late-stage development. Fasiglifam has the potential to be a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback